Earlier endovascular therapy within 24 hours associated with smaller infarct and better outcomes in LVO stroke.
This single-center prospective cohort study included 216 patients with anterior circulation large-vessel occlusion stroke who underwent endovascular therapy within 24 hours of symptom onset. The population was stratified into three groups based on onset-to-groin time: 0–6 hours, 6–12 hours, and 12–24 hours. The primary analysis compared outcomes across these time-stratified groups, while secondary outcomes included reperfusion quality, final infarct volume, infarct progression, NIHSS change, 90-day modified Rankin Scale, and serial inflammatory biomarkers measured up to 72 hours.
The main results demonstrated a clear stepwise decline in outcomes with treatment delay. Final infarct volume was 38.7 mL in the 0–6 hour group, increasing to 51.3 mL in the 6–12 hour group and 64.5 mL in the 12–24 hour group. Functional independence, defined as a modified Rankin Scale score of 0 to 2 at 90 days, occurred in 64.9% of the 0–6 hour group, compared with 50.0% in the 6–12 hour group and 35.7% in the 12–24 hour group. Reperfusion quality, assessed by mTICI 2b–3 rates and first-pass effect, was higher with earlier intervention.
Patients treated within the first 6 hours exhibited blunted peaks and faster resolution of inflammatory biomarkers, including IL-6, MMP-9, C-reactive protein, and the neutrophil-to-lymphocyte ratio. Safety data indicated that symptomatic intracranial hemorrhage, procedural complications, and in-hospital mortality were low and comparable across all three time strata. However, the study was limited by its observational design, which precludes causal inference. These results suggest that earlier endovascular therapy within the 24-hour window is associated with reduced tissue injury and improved clinical outcomes, but further research is needed to confirm these associations.